|
|
Social and Medical Costs of Dupuytren's Disease
Losenický, Jakub ; Votápková, Jana (advisor) ; Paulus, Michal (referee)
The thesis investigates the relative cost-effectiveness of two treatment methods of Dupuytren's disease (DD) - surgical fasciectomy and injectable collagenase - and assesses the impact of the two health technologies on the budget of the Czech Republic. For this purpose, cost-minimization analysis (CMA) and budget impact analysis (BIA) are employed and, importantly, both social and medical costs are taken into consideration. Concerning the CMA, different patients are modelled with respect to personal characteristics such as occupation, type of work (manual, non-manual) and income. In the BIA, data on DD occurrence in the Czech Republic from the National Register of Hospitalised Patients (NRHOSP) are analysed. We found that collagenase is a cost-minimizing treatment for a big majority of employees and manually working SMEs. On the other hand, collagenase turned out to be more expensive than fasciectomy for most of the non-manual SMEs. All things considered, collagenase appeared to be cheaper for most of the model patients. We also discovered that if all the patients in the dataset were treated with collagenase, the Czech state budget would annually save 1,685,452 CZK. The average annual costs of fasciectomy and collagenase were 41,334,049 CZK and 39,648,597 CZK, respectively. Powered by TCPDF (www.tcpdf.org)
|
|
|
Parameters of Drug Assessment in the Therapy of Rare Diseases
Ornstová, Eva ; Kostřiba, Jan (advisor) ; Klimeš, Jiří (referee)
Charles University in Prague, Faculty of Pharmacy in Hradec Králové Department of Social and Clinical Pharmacy Candidate Mgr. Eva Ornstová Consultant PharmDr. Jan Kostřiba, Ph.D Title of Thesis PARAMETERS OF DRUG ASSESSMENT IN THE THERAPY OF RARE DISEASES KEY WORDS: rare diseases, health technology assessment, health policy, drug policy OBJECTIVES The aim of this study was to find out how can the use of multiple criteria in Health technology assessment (HTA) influence outcome in different drug categories. Especially in relationship to orphan medicinal products. Next objective was to explore, which criteria are the most important in the value of the drug and to measure the difference in the preferences among three stakeholder groups in the Czech Republic. METHODS The set of 10 criteria was selected by the expert panel and 3 model treatments were described. Two-round questionnaire was developed and distributed among highly qualified representatives of three stakeholder groups (patients or carers, clinicians and policy makers). In the first round participants provided weights for each criterion by answering on the scale from 1 to 7. In second round participants scored model treatments according to their performance in each criterion. Normalized weights were combined with scores and treatments were...
|
|
|
Health technology assessment: case study on breast carcinoma treatment in the Czech Republic
Šlegerová, Lenka ; Bryndová, Lucie (advisor) ; Votápková, Jana (referee)
Health technology assessment: case study on breast carcinoma treatment in the Czech Republic Bc. Lenka Šlegerová January 4, 2019 Abstract This thesis proposes an original method for assessing total costs of med- ical treatment. It defines the semi-Markov model with four states that are associated with specific costs of the treatment, and not with patients' health statuses. This method is applied to individuals' treatment data drawn from the Czech clinical practice in the treatment of the metastatic HER2+ breast cancer. The aim is to assess the cost-effectiveness of adding medication per- tuzumab to the combination of trastuzumab+docetaxel within first-line therapy and to examine whether using individual data on Czech patients and the economic conditions leads to different results from foreign stud- ies. Furthermore, employing censored data from the clinical practice in the thesis complicates the estimation of patients' overall survival in compari- son to clinical-trials data that form random samples. Therefore, survival functions were not only estimated by the Kaplan-Meier estimator but also using the Cox proportional hazard model and the Accelerated failure time model that both control for the effects of included covariates. The addition of pertuzumab does not result in significantly longer pa- tients'...
|
|
|
Social and Medical Costs of Dupuytren's Disease
Losenický, Jakub ; Votápková, Jana (advisor) ; Paulus, Michal (referee)
The thesis investigates the relative cost-effectiveness of two treatment methods of Dupuytren's disease (DD) - surgical fasciectomy and injectable collagenase - and assesses the impact of the two health technologies on the budget of the Czech Republic. For this purpose, cost-minimization analysis (CMA) and budget impact analysis (BIA) are employed and, importantly, both social and medical costs are taken into consideration. Concerning the CMA, different patients are modelled with respect to personal characteristics such as occupation, type of work (manual, non-manual) and income. In the BIA, data on DD occurrence in the Czech Republic from the National Register of Hospitalised Patients (NRHOSP) are analysed. We found that collagenase is a cost-minimizing treatment for a big majority of employees and manually working SMEs. On the other hand, collagenase turned out to be more expensive than fasciectomy for most of the non-manual SMEs. All things considered, collagenase appeared to be cheaper for most of the model patients. We also discovered that if all the patients in the dataset were treated with collagenase, the Czech state budget would annually save 1,685,452 CZK. The average annual costs of fasciectomy and collagenase were 41,334,049 CZK and 39,648,597 CZK, respectively. Powered by TCPDF (www.tcpdf.org)
|
|
|
Zavedení nového postupu zdravotní péče pro český trh
Havran, Adam ; Lhotáková, Markéta (advisor) ; Cook, Gina (referee)
The objective of this work is to analyse the possibility of use of micro -- needles technology as the method of drug delivery in the Czech Republic. The characteristics of this product (application, connection with drug, etc.) suggest three possible target groups: patients, health care providers or pharmaceutical companies. One of the goals is to analyse legal requirements on such products, evaluate current market situation and according to this information choose the best group for the product consumption. Also product itself presents a challenge and there are several designs of micro -- needle or needleless drug applicators. Combined together, this study aims to find, whether is the Czech market able to accept new method of drug delivery, in which form and how can patient reach this technology.
|
|
| |
guest ::
